BIOMAT Database Logo BIOMAT Database Logo

[High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group]. 1990

T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
Dept. of Chemotherapy, Tokyo Metropolitan Komagome Hospital.

A multicenter cooperative study was conducted from June 1988 to July 1989 to evaluate the clinical efficacy of high-dose dl-Leucovorin (dl-LV) and 5-FU treatment in 61 cases of advanced gastric and colorectal cancer. The administration schedule was a 2-hour infusion of dl-LV (500 mg/m2) and an IV bolus of 5-FU (600 mg/m2), given 1 hour after the beginning of LV infusion. Patients (pts.) were treated q week x 6 then evaluated for response. Thirty one gastric cancer pts. were divided into two groups; nine pts. treated with 30 min. infusion of 5-FU, and the remaining 23 pts. treated with IV bolus. PR was obtained in 2/9 (22.2%) and in 7/22 (31.8%) of the first and second group, respectively. An overall response rate was 9/31 (29%). Thirty colorectal cancer pts. were divided the same: 13 pts. treated with 30 min. infusion of 5-FU and the remaining 17 pts. treated with IV bolus. PR was obtained in 2/13 (15.4%) and in 7/17 (41.2) of the first and second groups, respectively. An overall response rate was 9/30 (30%). Median survival time for the gastric cancer group was 9.4 months, and for the colorectal cancer group was 13.6 months. Toxicity was within acceptable limits. Toxic effects included diarrhea, stomatitis, anorexia and myelohypoplasia. Our data suggests that high dose LV and 5-FU seems to be a very promising combination and warrants a further investigation.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
March 1995, Cancer,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
Weekly high-dose 5-fluorouracil (5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer.
December 2001, Japanese journal of clinical oncology,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
June 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
September 2004, Clinical colorectal cancer,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
August 2002, Journal of chemotherapy (Florence, Italy),
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
Epidoxorubicin and high dose leucovorin plus 5-fluorouracil in advanced gastric cancer: a phase II study.
June 1993, Anti-cancer drugs,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
[Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].
August 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
[Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
January 1998, Srpski arhiv za celokupno lekarstvo,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
[A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
June 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
T Sasaki, and K Ota, and Y Sakata, and T Matsuoka, and A Wakui, and S Akazawa, and M Ogawa, and T Mukaiyama, and M Yoshino, and Y Sakai
[Cisplatin, 5-fluorouracil, and high-dose leucovorin for advanced esophageal cancer].
January 2003, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!